Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Total Non-Current Liabilities: 2022-2024

Historic Total Non-Current Liabilities for NewAmsterdam Pharma Co N.V (NAMS) over the last 1 years, with Sep 2024 value amounting to $41.5 million.

  • NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities was N/A to $41.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $41.5 million, marking a year-over-year change of. This contributed to the annual value of $50.9 million for FY2023, which is 438793.20% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Total Non-Current Liabilities stood at $41.5 million for Q3 2024, which was down 9.46% from $45.9 million recorded in Q2 2024.
  • NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities' 5-year high stood at $60.2 million during Q1 2024, with a 5-year trough of $10,499 in Q2 2023.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities averaged around $33.1 million, with its median value being $43.7 million (2024).
  • Data for NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities shows a peak YoY spiked of 438,793.20% (in 2023) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities (Quarterly) stood at $11,601 in 2022, then surged by 438,793.20% to $50.9 million in 2023, then surged by 436,674.93% to $41.5 million in 2024.
  • Its Total Non-Current Liabilities was $41.5 million in Q3 2024, compared to $45.9 million in Q2 2024 and $60.2 million in Q1 2024.